SpringWorks+400x400px.jpg
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024 06:30 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024 08:30 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024 06:30 ET | SpringWorks Therapeutics, Inc.
– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
February 22, 2024 07:00 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024 07:00 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 06:30 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 07:00 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks+400x400px.jpg
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023 16:05 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SWTXlogo.jpg
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 05, 2023 00:32 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SWTXlogo.jpg
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
December 04, 2023 16:13 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...